{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.23","upperLimit":"14.93","value":"3.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"PFS was measured from the time of treatment initiation until the time of progressive disease (PD) or death due to any cause for patients with an event, or until the time of last follow-up for patients who were progression free.","dispersionType":"Full Range","groups":[{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients who were treated with the \"3 times/week, every other week\" schedule.","id":"OG000","title":"Stratum 2"}],"paramType":"MEDIAN","populationDescription":"Non-progressed DIPG or H3K27M+ thalamic DMG patients who were enrolled on stratum 2 and received at least one dose of panobinostat were included in the analysis. Per the associated protocol objective, all dose levels on stratum 2 were combined to estimate the PFS for this stratum. Two patients who did not start protocol therapy were excluded.","reportingStatus":"POSTED","timeFrame":"From date on treatment until date of PD or death due to any cause or date of last follow-up","title":"Progression-free Survival (PFS) in Stratum 2","type":"SECONDARY","unitOfMeasure":"months"}